Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Piñana JL[au]:

Search results

Items: 1 to 50 of 85

1.

Partial T-cell depleted peripheral blood stem cell transplantation from HLA-identical sibling donors for patients with severe aplastic anemia.

Sanz J, Moscardó F, Montoro J, Cano I, Guerreiro M, Dasí MA, Solves P, Lorenzo I, Gómez-Segui I, Montesinos P, Mora E, Arnao M, Sempere A, Jarque I, Carretero C, Senent L, Vicente A, Andreu R, Luna I, Balaguer-Roselló A, Carpio N, Sanz GF, Sanz MA, Piñana JL.

Biol Blood Marrow Transplant. 2019 Sep 4. pii: S1083-8791(19)30560-9. doi: 10.1016/j.bbmt.2019.08.020. [Epub ahead of print]

PMID:
31493538
2.

An investigation of the utility of plasma Cytomegalovirus (CMV) microRNA detection to predict CMV DNAemia in allogeneic hematopoietic stem cell transplant recipients.

Talaya A, Giménez E, Pascual MJ, Gago B, Piñana JL, Hernández-Boluda JC, Vázquez L, García M, Serrano D, Hernández M, Albert E, Solano C, Navarro D.

Med Microbiol Immunol. 2019 Sep 3. doi: 10.1007/s00430-019-00632-7. [Epub ahead of print]

PMID:
31478067
3.

Incidence, risk factors, and outcome of pulmonary invasive fungal disease after respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients.

Piñana JL, Gómez MD, Montoro J, Lorenzo I, Pérez A, Giménez E, González-Barberá EM, Carretero C, Guerreiro M, Salavert M, Sanz G, Hernández-Boluda JC, Borrás R, Sanz J, Solano C, Navarro D.

Transpl Infect Dis. 2019 Aug 11:e13158. doi: 10.1111/tid.13158. [Epub ahead of print]

PMID:
31402532
4.

Cytomegalovirus (CMV) infection and risk of mortality in allogeneic hematopoietic stem cell transplantation (Allo-HSCT): A systematic review, meta-analysis, and meta-regression analysis.

Giménez E, Torres I, Albert E, Piñana JL, Hernández-Boluda JC, Solano C, Navarro D.

Am J Transplant. 2019 Sep;19(9):2479-2494. doi: 10.1111/ajt.15515. Epub 2019 Jul 24.

PMID:
31247126
5.

Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis.

Rodríguez-Veiga R, Montesinos P, Boluda B, Lorenzo I, Martínez-Cuadrón D, Salavert M, Pemán J, Calvillo P, Cano I, Acuña E, Villalba A, Piñana JL, Sanz J, Solves P, Senent L, Vicente A, Sempere A, Cervera J, Barragán E, Jarque I, Torres A, Sanz MA, Sanz GF.

Ann Hematol. 2019 Sep;98(9):2081-2088. doi: 10.1007/s00277-019-03744-5. Epub 2019 Jun 25.

PMID:
31240471
6.

Comparison of transfusion requirements in adult patients undergoing Haploidentical or single-unit umbilical cord blood stem cell transplantation.

Solves P, Sanz J, Gómez I, de la Puerta R, Arnao M, Montoro J, Piñana JL, Carretero C, Balaguer A, Guerreiro M, Andreu R, Rodríguez R, Montesinos P, Jarque I, Lorenzo JI, Carpio N, Sanz MÁ, Sanz GF.

Eur J Haematol. 2019 Sep;103(3):172-177. doi: 10.1111/ejh.13270. Epub 2019 Jul 3.

PMID:
31177565
7.

Pharmacokinetic/pharmacodynamic analysis of voriconazole against Candida spp. and Aspergillus spp. in allogeneic stem cell transplant recipients.

Perez-Pitarch A, Guglieri-Lopez B, Ferriols-Lisart R, Pérez A, Ezquer-Garín C, Hernández-Boluda JC, Piñana JL, Navarro D, Solano C, Alós-Almiñana M.

Ther Drug Monit. 2019 May 23. doi: 10.1097/FTD.0000000000000657. [Epub ahead of print]

PMID:
31136417
8.

Noninfectious Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation.

Balaguer-Rosello A, Bataller L, Piñana JL, Montoro J, Lorenzo I, Villalba A, Freiria C, Santiago M, Sevilla T, Muelas N, Guerreiro M, Carretero C, Gómez I, Solves P, Sanz MÁ, Sanz G, Sanz J.

Biol Blood Marrow Transplant. 2019 May 24. pii: S1083-8791(19)30335-0. doi: 10.1016/j.bbmt.2019.05.024. [Epub ahead of print]

PMID:
31132454
9.

Allogeneic stem-cell transplantation in HIV-1-infected patients with high-risk hematological disorders.

Kwon M, Bailén R, Balsalobre P, Jurado M, Bermudez A, Badiola J, Esquirol A, Miralles P, López-Fernández E, Sanz J, Yañez L, Colorado M, Piñana JL, Dorado N, Solán L, Martínez Laperche C, Buño I, Anguita J, Serrano D, Díez-Martin JL; Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH).

AIDS. 2019 Jul 15;33(9):1441-1447. doi: 10.1097/QAD.0000000000002209.

PMID:
30932952
10.

Kinetics of inflammatory biomarkers in plasma predict the occurrence and features of cytomegalovirus DNAemia episodes in allogeneic hematopoietic stem cell transplant recipients.

Talaya A, Giménez E, Vinuesa V, Pérez A, Amat P, Piñana JL, Albert E, Hernández-Boluda JC, Solano C, Navarro D.

Med Microbiol Immunol. 2019 Aug;208(3-4):405-414. doi: 10.1007/s00430-019-00594-w. Epub 2019 Mar 25.

PMID:
30911925
11.

Kinetics of Alphatorquevirus plasma DNAemia at late times after allogeneic hematopoietic stem cell transplantation.

Albert E, Solano C, Giménez E, Focosi D, Pérez A, Macera L, Piñana JL, Mateo EM, Boluda JCH, Maggi F, Navarro D.

Med Microbiol Immunol. 2019 Apr;208(2):253-258. doi: 10.1007/s00430-019-00586-w. Epub 2019 Mar 9.

PMID:
30852649
12.

Pulmonary cytomegalovirus (CMV) DNA shedding in allogeneic hematopoietic stem cell transplant recipients: Implications for the diagnosis of CMV pneumonia.

Piñana JL, Giménez E, Gómez MD, Pérez A, González EM, Vinuesa V, Hernández-Boluda JC, Montoro J, Salavert M, Tormo M, Amat P, Moles P, Carretero C, Balaguer-Roselló A, Sanz J, Sanz G, Solano C, Navarro D.

J Infect. 2019 May;78(5):393-401. doi: 10.1016/j.jinf.2019.02.009. Epub 2019 Feb 21.

PMID:
30797790
13.

Spontaneously-resolving episodes of cytomegalovirus DNAemia in allogeneic hematopoietic stem cell transplant recipients: Virological features and clinical outcomes.

Talaya A, Giménez E, Piñana JL, Albert E, Hernández-Boluda JC, Pérez A, Torres I, Solano C, Navarro D.

J Med Virol. 2019 Jun;91(6):1128-1135. doi: 10.1002/jmv.25426. Epub 2019 Feb 20.

PMID:
30735250
14.

Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group).

Garcia-Sanz R, Sureda A, de la Cruz F, Canales M, Gonzalez AP, Pinana JL, Rodriguez A, Gutierrez A, Domingo-Domenech E, Sanchez-Gonzalez B, Rodriguez G, Lopez J, Moreno M, Rodriguez-Salazar MJ, Jimenez-Cabrera S, Caballero MD, Martinez C.

Ann Oncol. 2019 Apr 1;30(4):612-620. doi: 10.1093/annonc/mdz009.

PMID:
30657848
15.

Effect of Sirolimus Exposure on the Need for Preemptive Antiviral Therapy for Cytomeglovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation.

Guglieri-Lopez B, Perez-Pitarch A, Garcia-Cadenas I, Gimenez E, Barba P, Rabella N, Hernandez-Boluda JC, Fox L, Valcarcel D, Esquirol A, Ferriols-Lisart R, Sierra J, Solano C, Navarro D, Martino R, Piñana JL.

Biol Blood Marrow Transplant. 2019 May;25(5):1022-1030. doi: 10.1016/j.bbmt.2019.01.012. Epub 2019 Jan 10.

PMID:
30639821
16.

Validation of a multivariable prediction model for post-engraftment invasive fungal disease in 465 adult allogeneic hematopoietic stem cell transplant recipients.

Rodríguez-Veiga R, Montesinos P, García E, Boluda B, Rojas R, Serrano J, Martínez-Cuadrón D, Martín C, Sanz J, Tabares S, Piñana JL, Lorenzo I, Montoro J, Salavert M, Pemán J, Jarque I, Solves P, Sanz GF, Torres A, Sanz MA.

Mycoses. 2019 May;62(5):418-427. doi: 10.1111/myc.12891. Epub 2019 Mar 8.

PMID:
30633829
17.

Failure of Cytomegalovirus-Specific CD8+ T Cell Levels at Viral DNAemia Onset to Predict the Eventual Need for Preemptive Antiviral Therapy in Allogeneic Hematopoietic Stem Cell Transplant Recipients.

Giménez E, Solano C, Piñana JL, Poch M, Mateo E, Albert E, Hernández-Boluda JC, Amat P, Remigia MJ, Pérez A, Navarro D.

J Infect Dis. 2019 Apr 16;219(9):1510-1512. doi: 10.1093/infdis/jiy746. No abstract available.

PMID:
30597050
18.

Factors influencing cytomegalovirus DNA load measurements in whole blood and plasma specimens from allogeneic hematopoietic stem cell transplant recipients.

Vinuesa V, Giménez E, Solano C, Albert E, Torres I, Pérez A, Hernández-Boluda JC, Piñana JL, Navarro D.

Diagn Microbiol Infect Dis. 2019 May;94(1):22-27. doi: 10.1016/j.diagmicrobio.2018.11.012. Epub 2018 Nov 22.

PMID:
30579656
19.

Invasive fungal disease in patients undergoing umbilical cord blood transplantation after myeloablative conditioning regimen.

Montoro J, Sanz J, Lorenzo JI, Montesinos P, Rodríguez-Veiga R, Salavert M, González E, Guerreiro M, Carretero C, Balaguer A, Gómez I, Solves P, Sanz GF, Sanz MA, Piñana JL.

Eur J Haematol. 2019 Apr;102(4):331-340. doi: 10.1111/ejh.13202. Epub 2019 Feb 12.

PMID:
30506598
20.

Clinical Effectiveness of Influenza Vaccination After Allogeneic Hematopoietic Stem Cell Transplantation: A Cross-sectional, Prospective, Observational Study.

Piñana JL, Pérez A, Montoro J, Giménez E, Gómez MD, Lorenzo I, Madrid S, González EM, Vinuesa V, Hernández-Boluda JC, Salavert M, Sanz G, Solano C, Sanz J, Navarro D.

Clin Infect Dis. 2019 May 17;68(11):1894-1903. doi: 10.1093/cid/ciy792.

PMID:
30239624
21.

T lymphocytes as therapeutic arsenal for patients with hematological malignancies.

Montoro J, Piñana JL, Sanz J, Guerreiro M.

Curr Opin Oncol. 2018 Nov;30(6):425-434. doi: 10.1097/CCO.0000000000000481. Review.

PMID:
30124521
22.

Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation.

Romero S, Montoro J, Guinot M, Almenar L, Andreu R, Balaguer A, Beneyto I, Espí J, Gómez-Codina J, Iacoboni G, Jarque I, López-Andújar R, Mayordomo-Aranda E, Montalar J, Pastor A, Pastor M, Piñana JL, Rojas-Ferrer N, Sánchez-Lázaro I, Sandoval J, Sanz G, Sanz MÁ, Solé A, Sanz J.

Leuk Lymphoma. 2019 Jan;60(1):142-150. doi: 10.1080/10428194.2018.1474462. Epub 2018 Jul 3.

PMID:
29966464
23.

Pre-engraftment cytomegalovirus DNAemia in allogeneic hematopoietic stem cell transplant recipients: incidence, risk factors, and clinical outcomes.

Solano C, Giménez E, Albert E, Mateo EM, Gómez M, Goterris R, Pérez A, Amat P, Hernández-Boluda JC, Poch M, Piñana JL, Navarro D.

Bone Marrow Transplant. 2019 Jan;54(1):90-98. doi: 10.1038/s41409-018-0251-0. Epub 2018 Jun 13.

PMID:
29899574
24.

Busulfan-based myeloablative conditioning regimens for haploidentical transplantation in high-risk acute leukemias and myelodysplastic syndromes.

Gayoso J, Balsalobre P, Kwon M, Herrera P, Bermúdez A, Sampol A, Jiménez S, López-Corral L, Serrano D, Piñana JL, Pascual MJ, Heras I, Bento L, Varela R, Humala K, Zabalza A, Laiglesia A, Bastos-Oreiro M, Pérez-Corral A, Martínez-Laperche C, Buño I, Díez-Martín JL; GETH (Grupo Español de Trasplante Hematopoyético), Spain.

Eur J Haematol. 2018 Sep;101(3):332-339. doi: 10.1111/ejh.13103. Epub 2018 Aug 3.

PMID:
29846964
25.

Community-acquired respiratory virus lower respiratory tract disease in allogeneic stem cell transplantation recipient: Risk factors and mortality from pulmonary virus-bacterial mixed infections.

Piñana JL, Gómez MD, Pérez A, Madrid S, Balaguer-Roselló A, Giménez E, Montoro J, González EM, Vinuesa V, Moles P, Hernández-Boluda JC, Salavert M, Calabuig M, Sanz G, Solano C, Sanz J, Navarro D.

Transpl Infect Dis. 2018 Aug;20(4):e12926. doi: 10.1111/tid.12926. Epub 2018 Jun 22.

PMID:
29809298
26.

Kinetics of torque teno virus DNA load in saliva and plasma following allogeneic hematopoietic stem cell transplantation.

Albert E, Torres I, Talaya A, Giménez E, Piñana JL, Hernández-Boluda JC, Focosi D, Macera L, Maggi F, Solano C, Navarro D.

J Med Virol. 2018 Sep;90(9):1438-1443. doi: 10.1002/jmv.25218. Epub 2018 May 25.

PMID:
29727487
27.

Validation of a plasma metabolomics model that allows anticipation of the occurrence of cytomegalovirus DNAaemia in allogeneic stem cell transplant recipients.

Monleón D, Talaya A, Giménez E, Vinuesa V, Morales JM, Hernández-Boluda JC, Pérez A, Piñana JL, Solano C, Navarro D.

J Med Microbiol. 2018 May 4. doi: 10.1099/jmm.0.000746. [Epub ahead of print]

PMID:
29724268
28.

Refractory cytomegalovirus DNAemia after allogeneic hematopoietic stem cell transplantation: when should genotypic drug resistance testing be requested?

Solano C, Talaya A, Giménez E, Albert E, Piñana JL, Hernández-Boluda JC, Pérez A, Navarro D.

Bone Marrow Transplant. 2018 Jun;53(6):787-790. doi: 10.1038/s41409-018-0191-8. Epub 2018 Apr 26. No abstract available.

PMID:
29700479
29.

Reduced intensity conditioning increases risk of severe cGVHD: identification of risk factors for cGVHD in a multicenter setting.

Afram G, Simón JAP, Remberger M, Caballero-Velázquez T, Martino R, Piñana JL, Ringden O, Esquirol A, Lopez-Corral L, Garcia I, López-Godino O, Sierra J, Caballero D, Ljungman P, Vazquez L, Hägglund H.

Med Oncol. 2018 Apr 25;35(6):79. doi: 10.1007/s12032-018-1127-2.

30.

Monitoring of oral cytomegalovirus DNA shedding for the prediction of viral DNAemia in allogeneic hematopoietic stem cell transplant recipients.

Pascual T, Solano C, Torres I, Talaya A, Giménez E, Vinuesa V, Piñana JL, Hernández-Boluda JC, Pérez A, Navarro D.

J Med Virol. 2018 Aug;90(8):1375-1382. doi: 10.1002/jmv.25185. Epub 2018 Apr 26.

PMID:
29663435
31.

Cytomegalovirus DNAemia Burden and Mortality Following Allogeneic Hematopoietic Stem Cell Transplantation: An Area Under a Curve-Based Investigational Approach.

Giménez E, Solano C, Vinuesa V, Hernández-Boluda JC, Albert E, Pérez A, Piñana JL, Navarro D.

Clin Infect Dis. 2018 Aug 16;67(5):805-807. doi: 10.1093/cid/ciy138. No abstract available.

PMID:
29617736
32.

Sirolimus exposure and the occurrence of cytomegalovirus DNAemia after allogeneic hematopoietic stem cell transplantation.

Piñana JL, Perez-Pitarch A, Guglieri-Lopez B, Giménez E, Hernandez-Boluda JC, Terol MJ, Ferriols-Lisart R, Solano C, Navarro D.

Am J Transplant. 2018 Dec;18(12):2885-2894. doi: 10.1111/ajt.14754. Epub 2018 Apr 24.

PMID:
29603596
33.

Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocyte infusions.

Ortí G, Sanz J, García-Cadenas I, Sánchez-Ortega I, Alonso L, Jiménez MJ, Sisinni L, Azqueta C, Salamero O, Badell I, Ferra C, de Heredia CD, Parody R, Sanz MA, Sierra J, Piñana JL, Querol S, Valcárcel D.

Exp Hematol. 2018 Jun;62:24-32. doi: 10.1016/j.exphem.2018.03.002. Epub 2018 Mar 8.

PMID:
29526774
34.

CD34+ Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome .

Barba P, Martino R, Zhou Q, Cho C, Castro-Malaspina H, Devlin S, Esquirol A, Giralt S, Jakubowski AA, Caballero D, Maloy M, Papadopoulos EB, Piñana JL, Fox ML, Márquez-Malaver FJ, Valcárcel D, Solano C, López-Corral L, Sierra J, Perales MA.

Biol Blood Marrow Transplant. 2018 May;24(5):964-972. doi: 10.1016/j.bbmt.2017.12.804. Epub 2018 Jan 2.

35.

Single umbilical cord blood with or without CD34+ cells from a third-party donor in adults with leukemia.

Sanz J, Kwon M, Bautista G, Sanz MA, Balsalobre P, Piñana JL, Solano C, Duarte R, Ferrá C, Lorenzo I, Martín C, Barba P, Pascual MJ, Martino R, Gayoso J, Buño I, Regidor C, de la Iglesia A, Montoro J, Díez-Martín JL, Sanz GF, Cabrera R.

Blood Adv. 2017 Jun 20;1(15):1047-1055. doi: 10.1182/bloodadvances.2017006999. eCollection 2017 Jun 27.

36.

Sclerodermatous Chronic Graft-versus-Host Disease Treated With Imatinib: A Dermatological Perspective.

Molés-Poveda P, Montesinos P, Sanz-Caballer J, de Unamuno B, Piñana JL, Sahuquillo A, Botella-Estrada R.

Actas Dermosifiliogr. 2018 Apr;109(3):241-247. doi: 10.1016/j.ad.2017.11.003. Epub 2017 Dec 15. English, Spanish.

PMID:
29254596
37.

Epidemiologic and Clinical Characteristics of Coronavirus and Bocavirus Respiratory Infections after Allogeneic Stem Cell Transplantation: A Prospective Single-Center Study.

Piñana JL, Madrid S, Pérez A, Hernández-Boluda JC, Giménez E, Terol MJ, Calabuig M, Navarro D, Solano C.

Biol Blood Marrow Transplant. 2018 Mar;24(3):563-570. doi: 10.1016/j.bbmt.2017.11.001. Epub 2017 Nov 15.

38.

Factors influencing platelet transfusion refractoriness in patients undergoing allogeneic hematopoietic stem cell transplantation.

Solves P, Sanz J, Freiria C, Santiago M, Villalba A, Gómez I, Montesinos P, Montoro J, Piñana JL, Lorenzo JI, Puig N, Sanz GF, Sanz MÁ, Carpio N.

Ann Hematol. 2018 Jan;97(1):161-167. doi: 10.1007/s00277-017-3168-6. Epub 2017 Nov 17.

PMID:
29150812
39.

Epstein-Barr virus DNA load kinetics analysis in allogeneic hematopoietic stem cell transplant recipients: Is it of any clinical usefulness?

Solano C, Mateo EM, Pérez A, Talaya A, Terol MJ, Albert E, Giménez E, Vinuesa V, Piñana JL, Boluda JCH, Navarro D.

J Clin Virol. 2017 Dec;97:26-32. doi: 10.1016/j.jcv.2017.10.016. Epub 2017 Nov 3.

PMID:
29096390
40.

The kinetics of torque teno virus plasma DNA load shortly after engraftment predicts the risk of high-level CMV DNAemia in allogeneic hematopoietic stem cell transplant recipients.

Albert E, Solano C, Giménez E, Focosi D, Pérez A, Macera L, Piñana JL, Boluda JCH, Maggi F, Navarro D.

Bone Marrow Transplant. 2018 Feb;53(2):180-187. doi: 10.1038/bmt.2017.235. Epub 2017 Oct 30.

PMID:
29084205
41.

Single-agent GvHD prophylaxis with tacrolimus after post-transplant high-dose cyclophosphamide is a valid option for haploidentical transplantation in adults with hematological malignancies.

Esquirol A, Pascual MJ, Ortiz M, Piñana JL, Ferra C, Garcia Cadenas I, Vilades I, Brunet S, Martino R, Sierra J.

Bone Marrow Transplant. 2017 Sep;52(9):1273-1279. doi: 10.1038/bmt.2017.111. Epub 2017 Jun 12.

PMID:
28604667
42.

When should preemptive antiviral therapy for active CMV infection be withdrawn from allogeneic stem cell transplant recipients?

Solano C, Giménez E, Piñana JL, Hernández-Boluda JC, Amat P, Vinuesa V, Navarro D.

Bone Marrow Transplant. 2017 Oct;52(10):1448-1451. doi: 10.1038/bmt.2017.109. Epub 2017 Jun 5. No abstract available.

PMID:
28581458
43.

A risk-adapted approach to treating respiratory syncytial virus and human parainfluenza virus in allogeneic stem cell transplantation recipients with oral ribavirin therapy: A pilot study.

Piñana JL, Hernández-Boluda JC, Calabuig M, Ballester I, Marín M, Madrid S, Teruel A, Terol MJ, Navarro D, Solano C.

Transpl Infect Dis. 2017 Aug;19(4). doi: 10.1111/tid.12729. Epub 2017 Jul 17.

PMID:
28544152
44.

Impact of cytomegalovirus DNAemia on overall and non-relapse mortality in allogeneic stem cell transplant recipients.

Solano C, Giménez E, Piñana JL, Albert E, Vinuesa V, Hernández-Boluda JC, Amat P, Navarro D.

Transpl Infect Dis. 2017 Aug;19(4). doi: 10.1111/tid.12717. Epub 2017 Jun 20.

PMID:
28471073
45.

A Time-to-Event Model for Acute Kidney Injury after Reduced-Intensity Conditioning Stem Cell Transplantation Using a Tacrolimus- and Sirolimus-based Graft-versus-Host Disease Prophylaxis.

Piñana JL, Perez-Pitarch A, Garcia-Cadenas I, Barba P, Hernandez-Boluda JC, Esquirol A, Fox ML, Terol MJ, Queraltó JM, Vima J, Valcarcel D, Ferriols-Lisart R, Sierra J, Solano C, Martino R.

Biol Blood Marrow Transplant. 2017 Jul;23(7):1177-1185. doi: 10.1016/j.bbmt.2017.03.035. Epub 2017 Apr 7.

46.

Infectious Complications after Umbilical Cord-Blood Transplantation from Unrelated Donors.

Montoro J, Piñana JL, Moscardó F, Sanz J.

Mediterr J Hematol Infect Dis. 2016 Oct 18;8(1):e2016051. eCollection 2016. Review.

47.

Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation.

Kharfan-Dabaja MA, Parody R, Perkins J, Lopez-Godino O, Lopez-Corral L, Vazquez L, Caballero D, Falantes J, Shapiro J, Ortí G, Barba P, Valcárcel D, Esquirol A, Martino R, Piñana JL, Solano C, Tsalatsanis A, Pidala J, Anasetti C, Perez-Simón JA.

Bone Marrow Transplant. 2017 Mar;52(3):438-444. doi: 10.1038/bmt.2016.269. Epub 2016 Nov 7.

PMID:
27819684
48.

GvHD prophylaxis with tacrolimus plus sirolimus after reduced intensity conditioning allogeneic transplantation: results of a multicenter study.

Parody R, López-Corral L, Lopez-Godino O, Martinez C, Martino R, Solano C, Barba P, Caballero D, García-Cadenas I, Piñana JL, Marquez-Malaver FJ, Vazquez L, Esquirol A, Boluda JC, Sanchez-Guijo F, Pérez-Simon JA.

Bone Marrow Transplant. 2016 Nov;51(11):1524-1526. doi: 10.1038/bmt.2016.163. Epub 2016 Jun 13. No abstract available.

PMID:
27295268
49.

Infections of the Central Nervous System after Unrelated Donor Umbilical Cord Blood Transplantation or Human Leukocyte Antigen-Matched Sibling Transplantation.

Balaguer Rosello A, Bataller L, Lorenzo I, Jarque I, Salavert M, González E, Piñana JL, Sevilla T, Montesinos P, Iacoboni G, Muelas N, Romero S, Carretero C, Montoro J, Ibáñez-Juliá MJ, Sanz G, Sanz MÁ, Sanz J.

Biol Blood Marrow Transplant. 2017 Jan;23(1):134-139. doi: 10.1016/j.bbmt.2016.10.005. Epub 2016 Oct 26.

50.

Lack of evidence for a reciprocal interaction between bacterial and cytomegalovirus infection in the allogeneic stem cell transplantation setting.

Vinuesa V, Solano C, Giménez E, Piñana JL, Boluda JC, Amat P, Navarro D.

Transpl Int. 2016 Nov;29(11):1196-1204. doi: 10.1111/tri.12831. Epub 2016 Sep 13.

Supplemental Content

Loading ...
Support Center